Chemotherapy for patients with hormone-refractory prostate cancer.
Joly
F
F
Tannock
I F
IF
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D004164:Diphosphonates / Q000008:administration & dosage; D000077143:Docetaxel; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
D001952:Bridged-Ring Compounds; D004164:Diphosphonates; D005938:Glucocorticoids; D043823:Taxoids; D000077143:Docetaxel; C080625:taxane; D014747:Vinblastine; D000077235:Vinorelbine; D006854:Hydrocortisone